What is BIOA's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for BIOA.

Stock Ratings / Health Care / BIOA / options

LYEL (30) RCKT (28) QTTB (53) LRMR (34) ⌘ Pro Terminal →

BioAge Labs Inc. (BIOA) Options Positioning, Max Pain & Unusual Sweeps

$5.87 -1.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.85

BioAge Labs Inc. (BIOA) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $269.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BIOA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BIOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, BioAge Labs Inc. (NASDAQ: BIOA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $5.87 (-1.18% 1D, market cap $269.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BIOA ranks #759 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BIOA compare to LYEL and RCKT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIOA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYEL (Lyell Immunopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $270.5M) and RCKT (Rocket Pharmaceuticals Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $267.9M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BIOA?

▼

Per BIOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001709941), BioAge Labs Inc. generated $9.0M in revenue (-95.9% YoY), -$80.6M in net income, and -$82.3M in free cash flow against $294.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.85 (-0.40%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BIOA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY BIOA SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (35% of score)

Altman Z-Score 5.66 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 43.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$5.57-0.2% Next Q

Q2 (-2Q)

Grade E$5.56-1.6% Next Q

Q3 (-1Q)

Grade E$5.47+7.3% Next Q

Current

Grade E$5.87-9.4% Hist 90D α

Trajectory: E (23) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BIOA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BIOA currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.25) and Max Pain ($6.16) forces dealer call-delta covering toward $27.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BIOA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BIOA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BIOA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BIOA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BIOA)

✓Walkthrough of BIOA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BIOA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -64.68%🛡️ HOLDING TREND SUPPORT

2026-11-03O $5.94H $5.94L $5.87C $5.87VOL 801.4K

RES: $31.91SUP: $3.96SMA50: $7.25SMA200: $15.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BIOA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BIOA Butterfly Map → + Track BIOA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BIOA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BIOA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BIOA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BIOA)

Health Care Rank #759 of 1016 ⚔️ LYEL vs BIOA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BIOA vs. LYEL, RCKT, QTTB, LRMR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioAge Labs Inc. (BIOA) ranks #759 by composite RQD confidence (31/100, grade E) and #529 by equity capitalization ($269.4M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with BIOA at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BIOA ACTIVE BioAge Labs Inc.	E	31/100	—	—	-35.0%	-1.18%	$269.4M	Benchmark Subject
LYEL Lyell Immunopharma Inc.	E	30/100	—	—	-35.0%	-2.34%	$270.5M	/lyel-vs-bioa →
RCKT Rocket Pharmaceuticals Inc.	E	28/100	—	—	-35.0%	-3.94%	$267.9M	/rckt-vs-bioa →
QTTB Q32 Bio Inc.	D+	53/100	8.9x	—	85.0%	+0.45%	$265.2M	/qttb-vs-bioa →
LRMR Larimar Therapeutics Inc.	E	34/100	—	—	-35.0%	-7.49%	$256.6M	/lrmr-vs-bioa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001709941

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioAge Labs Inc. (BIOA) reported GAAP revenue of $9.0M (-95.9% vs. FY2024 revenue of $218.9M , and -93.4% cumulative change since FY2023) , GAAP net income of -$80.6M, operating cash flow of -$81.6M, and free cash flow of -$82.3M (-58.7% YoY). On the balance sheet, BIOA closed FY2025 with $294.9M in total assets against $0 in total debt (Altman Z-Score: 5.66, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.0M	-$80.6M	-$81.6M	-$82.3M	$294.9M	$0
FY2024 (FY)	2024-12-31	$218.9M	-$71.1M	-$51.5M	-$51.9M	$358.2M	$2.5M
FY2023 (FY)	2023-12-31	$135.5M	-$63.9M	-$37.4M	-$37.4M	—	—

3. BIOA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BIOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BIOA compare to LYEL and RCKT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BIOA?

Where is BIOA trading relative to its 50-day, 200-day, and 52-week technical levels?

BIOA last traded at $5.87 (-1.18% on volume of 801,369 shares), positioning the stock -19.03% below its 50-day simple moving average ($7.25) and -62.54% below its 200-day simple moving average ($15.67). Across its 52-week range of $4.81 to $25.95, BIOA sits at the 5.0% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.14 to $6.60).

Direct Sub-Reports: BIOA RQD Cockpit BIOA 12M Forecast BIOA Earnings & Move BIOA Dividends & DRIP BIOA Insiders & 13F BIOA Whale Options BIOA Profit Sankey BIOA News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BIOA — BioAge Labs Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:39:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BIOA scores 31 out of 100, grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: the Fundamental Cash Engine scores 6 of 20 (ROIC -35%; FCF yield 0%), signaling that the business is not currently generating returns on capital or free cash flow. Whale 13F Flow scores 3 of 20 and Insider Conviction scores 3 of 20, indicating weak institutional and insider support in the rating model. Macro Regime Fit scores 8 of 20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 11 of 20, with the Altman Z-Score at 5.66, Piotroski F-Score at 2/9, and Debt/Equity at 0.5.

For a prospective investor, the profile reads as a pre-profit company with negative operating and net margins, where the valuation case rests on future outcomes not visible in the reported financials. The balance sheet is comparatively stronger than the cash engine: the Altman Z-Score is elevated and reported cash is substantial relative to reported debt, which gives runway but does not offset operating losses. Valuation tradeoffs are not measurable from the provided multiples, since P/E, EV/EBITDA, and EPS are unavailable. The sharp 52-week range ($4.81 - $25.95) against a current price of $5.94 illustrates high price volatility relative to the reported fundamentals.

Business

BioAge Labs Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. the market capitalization is $0.3B. Revenue is reported at $9.0M for FY 2025 and — for FY 2024 and FY 2023. — describes its specific products, customers, or monetization model.

Recent Catalysts & News Wire Analysis

Recent headlines per the news feed are all tagged to BIOA and include market-wire coverage from Yahoo! Finance Canada, TradingView, Yahoo Finance UK, Investing.com, The Globe and Mail, and Simply Wall St. The most substantive item is an Investing.com report titled around UBS initiating coverage at neutral with a focus on DME. Other items are generic market reports covering price action, institutional positioning, and fundamentals. Risk watch: the feed does not provide specific clinical, regulatory, or pipeline milestones. Proprietary signals per the Butterfly Supply-Chain Graph: —

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — Investors should note that the graph's absence means no quantified ripple effects can be drawn from the provided data.

Open Questions

What specific products or pipeline assets generate or are expected to generate the $9.0M FY 2025 revenue, and what are the timelines?
What is the cash runway implied by the FY 2025 burn rate relative to the $188.9M reported cash?
Why are EPS, P/E, and EV/EBITDA unavailable, and what would the earnings trajectory look like under a normalized scenario?
What drove the reported change in cash and debt between FY 2024 and FY 2025?
What institutional, insider, or congressional holdings exist, given that the holders section is empty?

BIOA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioAge Labs Inc. (BIOA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BIOA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 19h ago

BioAge Labs, Inc. (BIOA) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering BioAge Labs Inc. (BIOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 22h ago

BIOA Stock Price and Chart — NASDAQ:BIOA

TradingView report covering BioAge Labs Inc. (BIOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

BioAge Labs, Inc. (BIOA) stock price, news, quote and history

Yahoo Finance UK report covering BioAge Labs Inc. (BIOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

UBS initiates BioAge Labs stock coverage at neutral on DME focus

Investing.com report covering BioAge Labs Inc. (BIOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

BioAge Labs, Inc. (BIOA) Has a New Rating from UBS

The Globe and Mail report covering BioAge Labs Inc. (BIOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

BioAge Labs (NasdaqGS:BIOA) Stock Forecast & Analyst Predictions

Simply Wall St report covering BioAge Labs Inc. (BIOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

BioAge Labs, Inc. Estimates – NASDAQ:BIOA

TradingView report covering BioAge Labs Inc. (BIOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline

Yahoo! Finance Canada report covering BioAge Labs Inc. (BIOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BIOA Bull vs. Bear Conversation Board — What's Your Call at $5.87?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BIOA 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull Growth & Tech Investor 🐂 BULLISH 🎯 Target: $7.34 (+25.0%)

📌 Pinned Debate

Balance sheet strength, with an Altman Z-Score of 5.66 and reported cash of $188.9M against $0.0M debt, provides a financial cushion wh

Don't sleep on BIOA's setup in Health Care. Balance sheet strength, with an Altman Z-Score of 5.66 and reported cash of $188.9M against $0.0M debt, provides a financial cushion while the company funds operations.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $4.81 (-18.1%)

Spot @ $5.87

Operating margin of -60% and ROIC of -35% alongside FCF of $-82.3M in FY 2025 show the company is not yet generating cash from its oper

Sitting on the sidelines or leaning short BIOA above $5.87. Operating margin of -60% and ROIC of -35% alongside FCF of $-82.3M in FY 2025 show the company is not yet generating cash from its operations.. Until Fundamental Cash Engine (6/20) and FCF yield (0.0%) inflect higher, upside is capped near $25.95.